What question did this study set out to answer?

The study aims to evaluate the efficacy of P65-047, a novel TEAD degrader, in overcoming resistance to KRAS inhibitors in non-small cell lung cancer (NSCLC).

April 19, 2026

Abstract LB362: P65-047, a novel TEAD degrader, overcomes KRAS inhibitor resistance through Hippo pathway disruption in NSCLC

Key Points

The study aims to evaluate the efficacy of P65-047, a novel TEAD degrader, in overcoming resistance to KRAS inhibitors in non-small cell lung cancer (NSCLC).
Evaluated P65-047 in vivo using subcutaneous xenograft models of NSCLC.
Assessed TEAD protein degradation in vitro with various KRAS mutant cell lines.
Conducted combination treatments of P65-047 with KRAS inhibitors MRTX1133 and MRTX849.
P65-047 induced significant tumor regression in xenograft models compared to vehicle control.
In resistant cell lines, P65-047 combined with KRAS inhibitors restored growth suppression.
Mechanistic studies confirmed TEAD degradation and suppression of downstream gene transcripts in resistant platforms.

Abstract

Abstract Background: Allele-specific KRAS inhibitors (e. g. MRTX849, MRTX1133) show clinical benefit in KRAS-mutant NSCLC but face rapid development of resistance mediated by adaptive YAP/TEAD axis activation. TEAD degraders represent a rational mechanistic partner to intercept this bypass pathway and restore KRAS inhibitor sensitivity. Methods: P65-047, a cereblon-recruiting TEAD degrader, was evaluated in: (1) in vivo subcutaneous CDX models using NCI-H226 (NF2-/- mesothelioma, Hippo-dysregulated) and CALU-1 (KRASG12C/TP53-/- NSCLC) ; and (2) in vitro KRASG12D (LA1) /p53R172HΔG/+ (KP) syngeneic NSCLC mouse models including 344SQ-G12D and 344SQ-G12C (CRISPR/Cas9 modified to KRASG12C). Parental and MRTX1133/MRTX849-resistant derivatives were utilized. TEAD protein degradation and target gene suppression were assessed by Western blot and qPCR. Results: P65-047 monotherapy induced dose-dependent tumour regression in both xenograft models (vehicle-treated tumours progressed). In resistant cell models, P65-047 exhibited minimal single-agent activity but produced marked restoration of KRAS inhibitor-dependent growth suppression in combination settings: P65-047 + MRTX1133 resensitized MRTX1133-resistant 344SQ-M1133R cells, and P65-047 + MRTX849 resensitized MRTX849-resistant 344SQ-M849R cells in cell viability assays. Mechanistic studies confirmed on-target TEAD degradation and suppression of TEAD-regulated transcripts in resistant cells. Conclusions: P65-047 displays high efficacy, delivering robust in vivo tumour regression and strong resensitization in vitro, establishing TEAD degradation as a mechanistically validated strategy to overcome acquired resistance in KRAS-mutant NSCLC. These data support clinical advancement of TEAD degraders in patients with allele-specific KRAS inhibitor-refractory disease. Citation Format: Rajiv Sawant, Matthis Geitmann, Per Källblad, Samrat T. Kundu, Sofia Garza, Don L. Gibbons, Konrad Koehler, Peter Brandt. P65-047, a novel TEAD degrader, overcomes KRAS inhibitor resistance through Hippo pathway disruption in NSCLC abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts) ; 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86 (8Suppl): Abstract nr LB362.

Bookmark

Cite This Study

Sawant et al. (Fri,) studied this question.

synapsesocial.com/papers/69e47282010ef96374d8e893 https://doi.org/https://doi.org/10.1158/1538-7445.am2026-lb362

Bookmark